TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03426202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Oral Tablet
Description: modafinil 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo 200mg
Study: NCT04366063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy protocol 1
Description: Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy protocol 2
Description: Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
Study: NCT00582257

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
Study: NCT04295954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards.
Study: NCT01837004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CORTEX
Description: 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
Study: NCT00141739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant.
Study: NCT01555788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas for DiaPort system with Zone-MPC algorithm
Description: Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
Study: NCT01499225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 500mg per day(once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 1000mg per day(twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 2000mg per day(three times a day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSADOL[Zea mays L. extract] 35mg Tab
Description: \[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DENTISTA[Doxycycline hyclate] 20mg Cap
Description: DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
Study: NCT01499225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02877602

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: Transient Elastography
Study: NCT02429037

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: ABT-450 tablets
Study: NCT00304512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study: NCT06156722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm selection by IMSI
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm selection by IMSI and spermslow
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
Study: NCT03293576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet
Description: This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan).
Study: NCT02360319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any FDA approved antipsychotic agent
Description: Investigators are free to choose the most appropriate treatment for their clients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole long acting injectable formulation
Study: NCT03471169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirable TEG
Description: Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Undesirable TEG
Description: Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Study: NCT03297203

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
Study: NCT03123848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
Study: NCT02274857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVI Ablation
Description: Standard PVI procedure without FIRMap.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM-Guided Procedure and PVI
Description: FIRM-guided procedure followed by conventional ablation including PVI.
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets
Study: NCT00053495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus: ACAM2000 smallpox vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus: ACAM2000 smallpox vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus: ACAM2000 smallpox vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus: ACAM2000 smallpox vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccinia virus (calf lymph): Dryvax
Description: Group 5 dose: 1.0x10-8th PFU/ml
Study: NCT05379257

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Random dosage and time of furosemide
Description: Random dosage and time of furosemide, using a designated app
Study: NCT01361425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methildopa
Description: methildopa, 1,5g/day (500mg 8/8 hours, orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 500mg 8/8h, orally
Study: NCT03358056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
Study: NCT02569437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
Study: NCT02569437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline spray
Description: nasal saline sprays: 2 sprays each nostril three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonase
Description: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flonase
Description: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo pill to match doxycycline
Study: NCT04010630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Description: Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion.
Study: NCT04608006

Intervention type: DRUG
Intervention: Bupivacaine-fentanyl
Description: Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl

Intervention type: DRUG
Intervention: Bupivacaine-fentanyl
Description: Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl

Intervention type: DRUG
Intervention: Bupivacaine-fentanyl
Description: Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: ABT-267 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
Study: NCT02228070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: strabismus video goggles
Study: NCT02626832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural
Description: All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural
Description: All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural
Description: All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural
Description: All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules
Study: NCT02953847

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784

Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784

Intervention type: DRUG
Group type: OTHER
Intervention: Rifafour e-275
Description: Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
Study: NCT01464827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir capsules